image Follow Us:

Respiratio 2019; 9 (1-2): 30-35

DA LI JE HISTOLOŠKA GRAĐA ADENOKARCINOMA PLUĆA U
DIJAGNOSTIČKIM I TERAPIJSKIM UZORCIMA IDENTIČNA?


Tegeltija Dragana, Lovrenski Aleksandra, Vasiljević Tijana, Vanesa Sekeruš, Maksimović
Siniša, Kuhajda Ivan, Bijelović Milorad, Ivanić Milena, Miroslav Ilić

Original research

Naučni članak

doi: 10.26601/rsp.aprs.19.3

Apstrakt
Uvod:
Adenokarcinom (ADC) pluća ima heterogenu histološku građu. Dijagnostički uzorak (DU)
može da bude citološki ili histološki, najčešće se dobija bronhoskopijom. Kompletna hirurška resekcija
tumora predstavlja jedan od oblika lečenja obolelih od ADC.


Materijal i metode:U istraživanje je bilo uključeno 143 bolesnika sa dijagnostikovanim i hirurški
lečenim ADC pluća od 2010. do 2015. na Institutu za plućne bolesti Vojvodine. Analizirani podaci su
preuzeti iz istorije bolesti. Svi uzorci su reklasifikovani na osnovu kriterijuma SZO iz 2015. DU i
terapijski uzorak (TU) sa jednim histološkim aranžmanom smo smatrali homogenim (Ho), heterogeni
(He) su bili uzorci sa dva ili više aranžmana.


Rezultati:U istraživanje je bilo uključeno 84 muškaraca i 59 žena, 94 (66%) pušača, prosečne
starosti od 66 godina. DU su u 76% slučajeva dobijeni bronhobiopsijom i najčešće su bili Ho (69%). TU
dobijeni nakon lobektomije su bili najzastupljeniji (80%), najčešće He (75%). Acinarni i solidni
histološki tip je bio najzastupljeniji u obe grupe uzoraka.
Cilj rada je bio da se utvrdi da li je histološka građa adenokarcinoma pluća u dijagnostičkim i
terapijskim uzorcima identična.


Zaključak:Iako postoji statistički značajna razlika između histološke građe ADC u TU i DU
(p<0,001) acinarni tip je najzastupljeniji histološki tip (p=0,65883) uz podudaranje histoloških tipova
kod 106/143 (74%) bolesnika.


Ključne reči:Adenokarcinom, bronhobiopsija, hirurška terapija, histološka građa.

Full Article (PDF)

Literatura

1. Adler I. Primary malignant growths of the lungs and bronchi. New York: Longmans, Green; 1912.

[CrossRef]

 

2. International Agency for Research on Cancer: GLOBOCAN 2012; Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, Lyon, France 2012. Available from: http://globocan.iarc.fr Accessed February 12, 2013.

 

 

3. Henley JS, Richards TB, Underwood MJ, Eheman CR, Plescia M, Timothy A, et al. Lung cancer incidence trends among men and women United States,2005-2009. MMWR.2014 Jan 10;63(1):1-5.

 

 

4. El-Basmy A. Profile of lung cancer in Kuwait. Asian Pac J Cancer Prev. 2013;14(10):6181-4.

[CrossRef]

PMid:24289645

 

 

5. Lewis DR, Chen HS Lewis DR, Chen HS, Feurer EJ. SEER Cancer statistics review, 1975-2008. Bethesda, MD National Cancer Institute; 2010. Available from:http://seer.cancer.gov/csr/1975_2010/. Accessed October 20, 2013.

 

 

6. Hajmanoochehri F, Mohammadi N, Zohal MA, Sodagar A, Ebtehaj M. Epidemiological and clinicopathological characteristics of lung cancer in a teaching hospital in Iran. Asian Pac J Cancer Prev. 2014;15(6):2495-500.

[CrossRef]
PMid:24761853

 

 

7. Suda K, Sato K, Shimizu S, Tomizawa K, Takemoto T, Iwasaki T, et al. Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. BioMed Res Int. 2014;2014:645-81.

[CrossRef]
PMid:25371901 PMCid:PMC4209754

 

 

8. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013 Apr;8(4):461-8.

[CrossRef]
PMid:23486266

 

 

9. Furukawa M, Toyooka S, Ichimura K, Yamamoto H, Soh J, Hashida S, et al. Genetic alterations in lung adenocarcinoma with a micropapillary component. Mol Clin Oncol. 2016;4(2):195-200.

[CrossRef]
PMid:26893860 PMCid:PMC4734214

 

 

10. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(2):244-85.

[CrossRef]
PMid:21252716 PMCid:PMC4513953

 

 

11. Prudence R, Zoe W, Gavin W, Marissa D, Matthew C, Richard W. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. Thorac Oncol. 2011Sep;6(9):1496-504.

[CrossRef]
PMid:21642859

 

 

12. Yoshizawa A, Motoi N, Riely G, Sima CS, Gerald WL, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011. May;24(5):653-64.

[CrossRef]
PMid:21252858

 

 

13. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300.,


[CrossRef]
PMid:20610543

 

 

14. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23(4):1044-52.

[CrossRef]
PMid:22373539

 

 

15. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013 Jan;8(1):52- 61.

[CrossRef]
PMid:23242438

 

 

16. Stojšić J, Adzić T, Marić D, Subotić D, Milovanović I, Milenković B, et al. Histological types and age distribution of lung cancer operated patients over a 20-year period: a pathohistological based study. Srp Arh Celok Lek. 2011 Sep-Oct;139(9-10):619-24.

[CrossRef]
PMid:22069996

 

 

17. Paliogiannis P, Attene F, Cossu A, Defraia E, Porcu G, Carta A, et al. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Mol Med Rep. 2015 Jul;12(1):187-91.

[CrossRef]
PMid:25683726 PMCid:PMC4438954

 

 

18. Zhu P, Pan Q, Wang M. Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma. Thorac Cancer. 2015 Nov;6(6):709-14.

[CrossRef]
PMid:26557908 PMCid:PMC4632922

 

 

19. Balaban G, Žikić T, Perin B, Čanak V, Kopitović I, Jovanović S. Operabilnost bolesnika sa centralnim karcinomom bronha i atelektazom. Pneumon. 1998;36(1-4):11-4.

 

 

20. Wang S, Yu B, Chiu Chin Ng, Mercorella B, Selinger CI, O'Toole SA, et al. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Trans Lung Cancer Res. 2015 April; 4(2):119-25.

 

 

21. Gellert AR, Rudd RM, Sinha G, Geddes DM. Fiberoptic bronchoscopy: effect of multiple bronchial biopsies on diagnostic yield in bronchial carcinoma. Thorax. 1982 Sep;37(9):684-7.

[CrossRef]
PMid:6297116 PMCid:PMC459407

 

 

22. Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol. 2010 Apr;5(4):448-52.

[CrossRef]
PMid:20125040

 

 

23. Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol. 2014 May;12:148.

[CrossRef]
PMid:24885205 PMCid:PMC4067105

 

 

24. Liang Z, Zhang J, Zeng X, Gao J, Wu S, Liu T. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer. 2010 Jan;10(1):376.

[CrossRef]
PMid:20637128 PMCid:PMC2913962

 

 

25. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012 Nov;118(11):2889-99.

[CrossRef]
PMid:22020674 PMCid:PMC3369269

 

 

26. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 2004 Apr;57(4):383-7.

[CrossRef]
PMid:15047742 PMCid:PMC1770279

 

 

27. Furukawa M, Toyooka S, Ichimura K, Yamamoto H, Soh J, Hashida S, et al. Genetic alterations in lung adenocarcinoma with a micropapillary component. Mol Clin Oncol. 2016;4(2):195-200.

[CrossRef]
PMid:26893860 PMCid:PMC4734214

 

 

 

Dragana Tegeltija;
Univerzitet u Novom Sadu, Medicinski fakultet, Novi Sad, Srbija;
+381 63 550 792;
This email address is being protected from spambots. You need JavaScript enabled to view it.;
This email address is being protected from spambots. You need JavaScript enabled to view it.

Travel Turne Tranzito